baha the information company baha WebStation Terminal contact us Request free demo

baha is a leading provider of real-time market data, financial news, technology and solutions for the financial industry. baha offers real-time data terminals for professionals, global financial market data covering over 12 million financial instruments on more than 150 exchanges, as well as 24/7 breaking news with global coverage and free web and mobile apps. From a total of around 200 real-time data providers worldwide, only Reuters 1851, Bloomberg 1981 and now baha in 2021 were named after the founder.

Free License - non-commercial use only

Region

Time Zone

US
history
open
Sign Up / Login

For full-featured experience, please enable JavaScript.

HSBC Discount Zert MOR 30.12.2024/ DE000HG8YUD9 /

6/6/2024 7:56:06 PM	Chg.0.000	Bid6/6/2024	Ask-	Underlying	Strike price	Expiration date	Option type
6.340EUR	0.00%	6.340 Bid Size: 5,000	- Ask Size: -	MORPHOSYS AG O.N.	- -	12/30/2024	Call

TeleTrader 4/11 Novartis launches offer for Morphosys at €68 per share

TeleTrader 3/12 Germany clears Novartis' MorphoSys $2.9B deal

TeleTrader 2/5 Novartis to acquire MorphoSys for $2.9B

GlobeNewswire 6/3/2021 CONSTELLATION ALERT: Bragar Eagel & Squire, P.C. Investigates Sale of CNST and Encourages Investors ...

GlobeNewswire 6/2/2021 Royalty Pharma Announces $2.025 Billion Strategic Funding Partnership With MorphoSys

GlobeNewswire 4/27/2020 I-Mab and MorphoSys Announce First Patient Dosed in Phase 3 Clinical Trial of TJ202/MOR202 in r/r Mu...

GlobeNewswire 10/28/2019 MOR106 clinical development in atopic dermatitis stopped for futility

GlobeNewswire 4/23/2019 Galapagos and MorphoSys announce initiation of GECKO Phase 2 study with MOR106 in atopic dermatitis ...

GlobeNewswire 4/23/2019 Galapagos and MorphoSys announce initiation of GECKO Phase 2 study with MOR106 in atopic dermatitis ...

GlobeNewswire 9/13/2018 Galapagos and MorphoSys announce start of a Phase 1 subcutaneous bridging study with MOR106

GlobeNewswire 9/13/2018 Galapagos and MorphoSys announce start of a Phase 1 subcutaneous bridging study with MOR106

GlobeNewswire 9/12/2018 MorphoSys and Galapagos announce U.S. Antitrust Clearance for global license agreement for MOR106 wi...

GlobeNewswire 9/12/2018 MorphoSys and Galapagos announce U.S. Antitrust Clearance for global license agreement for MOR106 wi...

GlobeNewswire 7/19/2018 MorphoSys and Galapagos Sign Global License Agreement for MOR106 with Top Pharma Partner

GlobeNewswire 7/19/2018 MorphoSys and Galapagos Sign Global License Agreement for MOR106 with Top Pharma Partner

GlobeNewswire 5/1/2018 Galapagos and MorphoSys announce initiation of the IGUANA Phase 2 clinical trial with MOR106 in atop...

GlobeNewswire 5/1/2018 Galapagos and MorphoSys announce initiation of the IGUANA Phase 2 clinical trial with MOR106 in atop...

GlobeNewswire 4/19/2018 Nasdaq Welcomes MorphoSys AG (Nasdaq: MOR) to The Nasdaq Stock Market

GlobeNewswire 2/17/2018 Galapagos and MorphoSys present results from a Phase 1 study with MOR106 in atopic dermatitis as lat...

GlobeNewswire 2/17/2018 Galapagos and MorphoSys present results from a Phase 1 study with MOR106 in atopic dermatitis as lat...

GlobeNewswire 9/27/2017 Galapagos and MorphoSys report first promising signs of clinical activity in a Phase 1 study with IL...

GlobeNewswire 9/27/2017 Galapagos and MorphoSys report first promising signs of clinical activity in a Phase 1 study with IL...

GlobeNewswire 8/31/2017 Aptevo Therapeutics and MorphoSys End Joint Development and Commercialization Agreement for MOR209/E...

GlobeNewswire 12/15/2016 Aptevo Therapeutics Amends Collaboration Agreement with MorphoSys AG for Novel Immunotherapeutic, MO...

GlobeNewswire 12/13/2016 MorphoSys Starts Phase 2 Trial of MOR208 in Combination with Idelalisib in Patients with Relapsed or...